Histological improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether mepolizumab 2.5 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Improvement in symptoms · GORD in children over 1 year of age
1 finding from 1 review
Adverse events · GORD in children over 1 year of age
1 finding from 1 review
Endoscopic improvement (dichotomous) · GORD in children over 1 year of age
1 finding from 1 review
pH indices ‐ not measured · GORD in children over 1 year of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to adequate sedation (minutes or as measured by specific validated scales such as the Ramsay Sedation Score) · children undergoing neurodiagnostic procedures
1 finding from 1 review
Proportion of children with inadequate level of sedation (Ramsay score below 4) · children undergoing neurodiagnostic procedures
Chloral hydrate oral (100 mg/kg or 75 mg/kg) probably leads to lower proportion of children with inadequate level of sedation (Ramsay… compared with midazolam (intranasal 0.2 mg/kg or oral 0.5 mg/kg) (moderate certainty).
1 finding from 1 review